SOPHiA GENETICS' 10th Social Media Newsletter
As we move forward into 2025, SOPHiA GENETICS is proud to reflect on a month filled with impactful moments, key collaborations, and major advancements in data-driven medicine. Let’s take a look at our highlights:
Shaping the Future of Healthcare at JPM 2025
At JPM 2025, our leadership team — Jurgi Camblong , Ross Muken , George Cardoza , Philippe Menu , as well as Kellen Sanger and Jess Lambe — connected with industry leaders, partners, and innovators to shape the future of healthcare.
A standout moment was joining Jensen Huang and the 英伟达 team at their exclusive partner event, discussing how cutting-edge technology is redefining medicine.
These conversations reinforced our commitment to advancing precision oncology, multimodal analytics, and global access to data-driven insights.
SOPHiA GENETICS’ Entry Into MRD
We're thrilled to introduce OncoPortal? Mutation Tracker, a longitudinal MRD tracking tool designed for disease monitoring in oncology.
The OncoPortal? Mutation Tracker augments the SOPHiA DDM? Platform’s core analytical capabilities to allow clinical researchers to longitudinally monitor evolving genomic variants across multiple time points, providing a comprehensive view of disease evolution.
A Story of Hope: Hospital de Amor, Brazil
A touching story from Hospital de Amor in S?o Paulo reminds us why our mission matters now more than ever.
With the dedication of Dr. Rui Manuel Reis , Scientific Director, and Dr. Gustavo Ramos Teixeira, Pathologist, supported by SOPHiA GENETICS’ technology, data-driven insights are making a real impact in oncology.
Unlocking the Power of Data-Driven Medicine: Jurgi Camblong’s Thought Leadership
A recent Le Monde article highlights the impact of data-driven medicine for women with HER2-negative breast cancer—showing how genomic testing can improve treatment decisions and reduce unnecessary procedures.
Jurgi Camblong , CEO & Co-founder of SOPHiA GENETICS, shares why these innovations must be more accessible to all health systems, ensuring equitable, high-quality care worldwide.
领英推荐
UroCCR Project Spotlight?
SOPHiA GENETICS and UroCCR — the French Kidney Cancer Network — have joined forces in harnessing machine learning (ML) to advance kidney cancer research and develop the UroPredict algorithm.?
Recently, we had the opportunity to interview Dr. Ga?lle Margue and Prof. Jean-Christophe BERNHARD at Bordeaux University Hospital to learn more about this collaboration and the benefits of using AI-powered multimodal approaches to provide improved patient care.?
New Case Study Alert: Henry Ford Health
We’re excited to share our latest case study with Henry Ford Health!
Henry Ford Health needed to unify three critical workflows—hereditary cancer, cystic fibrosis, and pharmacogenetics testing—which had previously relied on separate assays.
By adopting a clinical exome-based approach, Henry Ford Health gained the ability to cover all relevant genes in a single workflow, with targeted analyses for each application.
Live from the Festival of Genomics & Biodata – Visit Booth 91!
Come meet us today at the UK’s biggest genomics event and explore how SOPHiA GENETICS is shaping the future of precision medicine:
?? How we revolutionize the future of data-driven medicine, together
?? How the New Generation of our AI-powered SOPHiA DDM Platform is transforming genomic insights in more than 70 countries globally
?? Our groundbreaking innovations and novel partnerships
Are you in London? We can't wait to connect!
If you're as passionate about transforming healthcare as we are, don't miss out on our future updates. ?? Subscribe to our monthly newsletter and stay at the forefront of data-driven medicine.